DexCom (DexCom) Change In Working Capital : $-29 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is DexCom Change In Working Capital?

DexCom's change in working capital for the quarter that ended in Mar. 2024 was $19 Mil.

DexCom's change in working capital for the fiscal year that ended in Dec. 2023 was $3 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

DexCom Change In Working Capital Historical Data

The historical data trend for DexCom's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Change In Working Capital Chart

DexCom Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

6.10

-20.80

-132.00

26.70

3.20

DexCom Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															51.50	46.80	163.00	-258.10	19.00

DexCom Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

DexCom Change In Working Capital Related Terms

Thank you for viewing the detailed overview of DexCom's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

DexCom (DexCom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

DXCM:Mexico DC4:Germany DC4:Germany DC4:Germany DC4:Germany D1EX34:Brazil DXCM:Austria

Address

6340 Sequence Drive, San Diego, CA, USA, 92121

Website

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Executives

Sadie Stern	officer: Chief Human Resources Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman	director
Kevin R Sayer	director
Jereme M Sylvain	officer: SVP, Finance & CAO	6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach	officer: SVP, Research & Development	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos	director	754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown	officer: EVP, Chief Legal Officer	6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli	officer: Vice President Legal Affairs	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan	officer: EVP Chief Technology Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan	officer: EVP Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller	director	TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan	officer: *	6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj	officer: SVP Information Technology	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn	officer: EVP, Global Revenue	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121